NCT01971203View on ClinicalTrials.gov

Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat

NACompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Major Depressive DisorderGeneralized Anxiety Disorder
Interventions
DRUG

seroquel xr

Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day

BEHAVIORAL

CBT

16 weeks of treatment

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER